Literature DB >> 1801656

Response of scleroderma fibroblasts to various growth factors.

K Takehara1, Y Soma, A Igarashi, K Kikuchi, A Moro, Y Ishibashi.   

Abstract

Abnormal growth regulation in lesional skin fibroblasts may be related to scleroderma pathogenesis. We report on the abnormal response of cultured fibroblasts derived from sclerotic lesions to various growth factors. We investigated the responses of skin fibroblasts (10 strains) and normal fibroblasts (9 strains) to the growth factors as PDGF, TGF-beta 1, EGF and basic FGF. Experiments were conducted during the proliferation and confluent stages. PDGF, EGF and basic FGF stimulated fibroblast growth during the proliferation and confluent stages, but the response of scleroderma fibroblasts was significantly lower than that of normal fibroblasts. TGF-beta 1 slightly stimulated confluent fibroblast growth and inhibited proliferating fibroblasts, and the response of scleroderma fibroblasts exceeded that of normal fibroblasts. The decreased response to growth-stimulating factors observed in scleroderma fibroblasts suggests that cultured fibroblasts derived from scleroderma lesions were already senescent because they have been activated by growth-stimulating factors and repeatedly divided in vivo. Thus, abnormal growth regulation of skin fibroblasts may be partially related to the pathogenesis of scleroderma.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1801656     DOI: 10.1007/BF00371783

Source DB:  PubMed          Journal:  Arch Dermatol Res        ISSN: 0340-3696            Impact factor:   3.017


  26 in total

1.  The effects of various growth factors on endothelial cell survival in vitro.

Authors:  T Etoh; K Takehara; A Igarashi; Y Ishibashi
Journal:  Biochem Biophys Res Commun       Date:  1989-08-15       Impact factor: 3.575

2.  Co-ordinate increase in the expression of type I and type III collagen genes in progressive systemic sclerosis fibroblasts.

Authors:  S A Jimenez; G Feldman; R I Bashey; R Bienkowski; J Rosenbloom
Journal:  Biochem J       Date:  1986-08-01       Impact factor: 3.857

3.  A fibroblast mitogen present in scleroderma but not control sera: inhibition by proteinase inhibitors.

Authors:  E C LeRoy; M B Kahaleh; S Mercurio
Journal:  Rheumatol Int       Date:  1983       Impact factor: 2.631

4.  Increased procollagen mRNA levels in scleroderma skin fibroblasts.

Authors:  P N Graves; I K Weiss; J S Perlish; R Fleischmajer
Journal:  J Invest Dermatol       Date:  1983-02       Impact factor: 8.551

5.  Reduced response of scleroderma fibroblasts to fibroblast growth factor.

Authors:  K Nishioka; Y Kobayashi; I Katayama; S Sano
Journal:  Arch Dermatol Res       Date:  1984       Impact factor: 3.017

6.  Scleroderma: increased biosynthesis of triple-helical type I and type III procollagens associated with unaltered expression of collagenase by skin fibroblasts in culture.

Authors:  J Uitto; E A Bauer; A Z Eisen
Journal:  J Clin Invest       Date:  1979-10       Impact factor: 14.808

7.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.

Authors: 
Journal:  Arthritis Rheum       Date:  1980-05

8.  Collagen types synthesized in dermal fibroblast cultures from patients with early progressive systemic sclerosis.

Authors:  R E Gay; R B Buckingham; R K Prince; S Gay; G P Rodnan; E J Miller
Journal:  Arthritis Rheum       Date:  1980-02

9.  Progressive systemic sclerosis (PSS, scleroderma) dermal fibroblasts synthesize increased amounts of glycosaminoglycan.

Authors:  R B Buckingham; R K Prince; G P Rodnan
Journal:  J Lab Clin Med       Date:  1983-05

10.  Transforming growth factor-beta modulates the high-affinity receptors for epidermal growth factor and transforming growth factor-alpha.

Authors:  J Massagué
Journal:  J Cell Biol       Date:  1985-05       Impact factor: 10.539

View more
  3 in total

1.  Low serum fibroblast growth factor 2 levels not accompanied by increased serum pentraxin 3 levels in patients with systemic sclerosis.

Authors:  Ufuk İlgen; Müçteba Enes Yayla; Nurşen Düzgün
Journal:  Clin Rheumatol       Date:  2016-11-22       Impact factor: 2.980

Review 2.  Emerging disease-modifying therapies for sickle cell disease.

Authors:  Marcus A Carden; Jane Little
Journal:  Haematologica       Date:  2019-08-14       Impact factor: 9.941

Review 3.  In utero Therapy for the Treatment of Sickle Cell Disease: Taking Advantage of the Fetal Immune System.

Authors:  Alba Saenz de Villaverde Cortabarria; Laura Makhoul; John Strouboulis; Giovanna Lombardi; Eugene Oteng-Ntim; Panicos Shangaris
Journal:  Front Cell Dev Biol       Date:  2021-01-22
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.